Clinical Trials for Non-Small Cell Lung Cancer

A Phase Ib Study of Vismodegib and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (ML43922)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: The trial targets patients aged 18 and older with recurrent or metastatic non-small cell lung cancer who have exhausted curative treatments, investigating a combination of vismodegib, an inhibitor of the Hedgehog signaling pathway, and atezolizumab, a PD-L1 immune checkpoint inhibitor. Participants must have measurable disease and will receive treatment in a non-randomized, open-label single arm to evaluate safety, tolerability, and efficacy.

ClinicalTrials.gov ID: NCT06616623

Phase 2 Study to Evaluate Reduced Dose Chemotherapy in Combination With Anti-PD-1 Therapy as First Line Treatment in Vulnerable or Older Adults (Vulnerable or Age ≥70) With Advanced PD-L1 TPS <50% Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial targets vulnerable or older adults aged 70 or above with advanced non-small cell lung cancer (NSCLC) and a PD-L1 TPS of less than 50%, assessing the safety and efficacy of reduced dose chemotherapy with carboplatin and paclitaxel or pemetrexed (depending on histology), in combination with Pembrolizumab, an anti-PD-1 antibody therapy.

ClinicalTrials.gov ID: NCT06731413

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls patients with previously untreated, locally advanced or metastatic non-squamous NSCLC with a documented KRAS G12C mutation, randomizing them to receive adagrasib (a selective KRAS G12C inhibitor) plus pembrolizumab and platinum-pemetrexed chemotherapy versus placebo plus pembrolizumab and chemotherapy. Patients may have asymptomatic, untreated brain metastases ≤ 20 mm; prior KRAS G12C inhibitor therapy is not allowed.

ClinicalTrials.gov ID: NCT06875310

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic NSCLC—including those post standard therapies, unresectable stage III after chemoradiotherapy, and resectable stage II/III eligible for perioperative treatment—and investigates BNT116, an mRNA cancer vaccine targeting six NSCLC antigens, as monotherapy or combined with standard chemotherapy, PD-1/CTLA-4 inhibition (cemiplimab, BNT316), and antibody–drug conjugates. Eligibility generally excludes patients with targetable mutations for which approved therapies exist.

ClinicalTrials.gov ID: NCT05142189

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 As a Single Agent and in Combination Therapy in Patients with Selected Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced solid tumors—including specific expansion cohorts for RCC, NSCLC, and PD-L1-negative NSCLC—who have progressed after or cannot tolerate standard therapies or are treatment naïve for metastatic disease without actionable mutations. Patients receive STK-012, an engineered IL-2 partial agonist that selectively stimulates CD25+ T cells with reduced toxicity risk, as monotherapy or in combination with pembrolizumab, and in NSCLC, with pembrolizumab plus pemetrexed and carboplatin.

ClinicalTrials.gov ID: NCT05098132

A First-In-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Administered by Parenteral Route in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced, DLL3-positive small cell lung cancer, large cell neuroendocrine lung carcinoma, or neuroendocrine carcinoma of any origin who have progressed after standard therapies, to receive BI 764532—a parenterally administered DLL3/CD3 bispecific T-cell engager antibody. Eligible patients must have good performance status and adequate organ function, and may include those with treated or stable brain metastases.

ClinicalTrials.gov ID: NCT04429087

A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) As First-Line Therapy in Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with treatment-naïve, metastatic EGFR-mutant NSCLC (exon 19 deletion, L858R, or select uncommon mutations) to receive osimertinib plus tegavivint, a TBL1 inhibitor that disrupts Wnt/β-catenin signaling, as first-line therapy. Patients must have an ECOG PS 0–2 and may have asymptomatic, treated brain metastases.

ClinicalTrials.gov ID: NCT04780568

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced solid tumors harboring a KRAS G12C mutation, including both previously treated and some untreated NSCLC and CRC patients, to evaluate the oral KRAS G12C inhibitor LY3537982 (olomorasib) as monotherapy or in combination with pembrolizumab, cetuximab, pemetrexed, cisplatin, or carboplatin.

ClinicalTrials.gov ID: NCT04956640

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with stage IV or recurrent non-squamous NSCLC, PD-L1 ≥1%, no actionable driver mutations, and good performance status, comparing first-line nivolumab (PD-1 inhibitor) plus relatlimab (LAG-3 inhibitor) with chemotherapy versus pembrolizumab plus chemotherapy. Prior checkpoint inhibitor therapy, untreated CNS metastases, and active autoimmune diseases are exclusion criteria.

ClinicalTrials.gov ID: NCT06561386

Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic squamous or non-squamous NSCLC (excluding tumors with actionable genomic alterations), either CPI-experienced or treatment-naive with documented PD-L1 expression, to receive rilvegostomig (AZD2936), an intravenous bispecific anti-TIGIT/anti-PD-1 antibody designed to enhance T-cell antitumor activity. Patients must have ECOG 0-1 and adequate organ function.

ClinicalTrials.gov ID: NCT04995523